Published on Drug Pipeline (https://www.drugpipeline.net) Home > Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017 Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017 Publication ID: GMD0717059 Publication Date: July 18, 2017 Pages: 66 Publisher: Global Markets Direct Region: Global [1] Publication License Type * Single User License (PDF), $2,000.00 $2,000.00 Site License (PDF), $4,000.00 Global License (PDF), $6,000.00 Please choose the suitable license type from above. More details are at given under tab "Report License Types" below. Add to cart
Description: Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017, provides an overview of the Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline landscape. "Diabetic neuropathy is nerve damage caused by diabetes. The type of neuropathy occurring in the arms, hands, legs and feet is known as diabetic peripheral neuropathy. Symptoms include numbness or tingling in the feet pain or discomfort in the feet or legs-including prickly, sharp pain or burning feet, muscle weakness and loss of muscle tone in the feet and lower legs, loss of balance, dry feet and cracked skin. The predisposing factors include diabetes, msmoking and kidney diseases. Treatment includes antidepressants, anti-seizure and opioid analgesics." Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Peripheral Neuropathy - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 6, 3 and 7 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively. Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Peripheral Neuropathy (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Diabetic Peripheral Neuropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Peripheral Neuropathy (Metabolic Disorders) Reasons to buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Diabetic Peripheral Neuropathy (Metabolic Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it s most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Diabetic Peripheral Neuropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline. Table Of Contents: Table of Contents List of Tables List of Figures
Introduction Global Markets Direct Report Coverage Diabetic Peripheral Neuropathy - Overview Diabetic Peripheral Neuropathy - Therapeutics Development Pipeline Overview Pipeline by Companies Pipeline by Universities/Institutes Products under Development by Companies Products under Development by Universities/Institutes Diabetic Peripheral Neuropathy - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development Achelios Therapeutics Inc Celgene Corp Commence Bio Inc Grunenthal GmbH Immune Pharmaceuticals Inc KPI Therapeutics Inc Medifron DBT Co Ltd Mitsubishi Tanabe Pharma Corp Novaremed Ltd Reata Pharmaceuticals Inc Relief Therapeutics Holding AG ViroMed Co Ltd Diabetic Peripheral Neuropathy - Drug Profiles (amitriptyline + ketamine hydrochloride) - Drug Profile AAD-2004 - Drug Profile atexakin alfa - Drug Profile
BNV-222 - Drug Profile CMB-200 - Drug Profile CNV-2197944 - Drug Profile ketoprofen - Drug Profile KU-32 - Drug Profile MDR-16523 - Drug Profile MDR-652 - Drug Profile MT-8554 - Drug Profile NRD-135SE1 - Drug Profile PDA-002 - Drug Profile
pirenzepine hydrochloride - Drug Profile Small Molecules for Pain - Drug Profile Small Molecules to Inhibit Hsp90 for Peripheral Neuropathy and Neurodegenerative Disorders - Drug Profile sodium nitrite SR - Drug Profile U-2902 - Drug Profile VM-202 - Drug Profile Diabetic Peripheral Neuropathy - Dormant Projects Diabetic Peripheral Neuropathy - Discontinued Products Diabetic Peripheral Neuropathy - Product Development Milestones Featured News & Press Releases Sep 08, 2016: ViroMed proceeding with the World s first phase III gene therapy clinical trial for diabetic peripheral neuropathy Jun 27, 2016: VM BioPharma Announces First Patient Dosed in Phase 3 Study of Gene Therapy Candidate, VM202, in Painful Diabetic Peripheral Neuropathy Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition Appendix Methodology Coverage Secondary Research Primary Research
Expert Panel Validation Contact Us Disclaimer List of Tables List of Tables Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Achelios Therapeutics Inc, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Celgene Corp, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Commence Bio Inc, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Grunenthal GmbH, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by KPI Therapeutics Inc, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Medifron DBT Co Ltd, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Novaremed Ltd, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Reata Pharmaceuticals Inc, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by Relief Therapeutics Holding AG, H2 2017 Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co Ltd, H2 2017 Diabetic Peripheral Neuropathy - Dormant Projects, H2 2017 Diabetic Peripheral Neuropathy - Discontinued Products, H2 2017 List of Figures List of Figures Number of Products under Development for Diabetic Peripheral Neuropathy, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017 Companies Mentioned: Achelios Therapeutics Inc Celgene Corp Commence Bio Inc Grunenthal GmbH Immune Pharmaceuticals Inc KPI Therapeutics Inc Medifron DBT Co Ltd Mitsubishi Tanabe Pharma Corp Novaremed Ltd Reata Pharmaceuticals Inc Relief Therapeutics Holding AG ViroMed Co Ltd License Types: Single User License (PDF) This license allows for use of a publication by one person. This person may print out a single copy of the publication. This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. This person cannot share the publication (or any information contained therein) with any other person or persons. Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Site License (PDF)* This license allows for use of a publication by all users within one corporate location, e.g. a regional office. These users may print out a single copy of the publication. These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization. Customers who infringe these license terms are liable for a Global license fee. Global License (PDF)* This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company. Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization. These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher. *If Applicable. No. 1101, Golden Square, 3rd Floor, 24th Main, J P Nagar, 1st Phase, Bangalore, Karnataka, India- 560078 India: +91-8762746600 info@domain.com NAVIGATE --> About Us Reports by Region FAQ Privacy Policy TERMS & CONDITIONS CONTACT
RECENT POSTS What is drug pipeline research? March 20 How to use market research to bring your idea to life? March 11 How to gain business insights using syndicated market research? March 10 Source URL: https://www.drugpipeline.net/global-markets-direct/diabetic-peripheral-neuropathy-pipeline-review-h2-2017 Links [1] https://www.drugpipeline.net/region/global